Transaction · 0001493152-26-039693

Plump Andrew Stewart

Plump Andrew Stewart, PRES, R, D, reported an open-market or private sale at TAKEDA PHARMACEUTICAL CO LTD involving 19651.000000 shares for an estimated $363346.99. Reported holdings after the transaction were 261656.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, R, D
TAKTAKEDA PHARMACEUTICAL CO LTD
Filing timeAug 21
Trade dateAug 19, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$18.18
Pre-filing
1mo ago -6.2%1w ago -4.2%1d ago -0.7%
Returns since
7d -0.8%30d -0.8%90d -0.8%180d -0.8%1y -0.8%

TAK price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
TAK since 2026-08-21Filed 14 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001493152-26-039693
American Depositary Shares
Transaction date
Aug 19, 2026
Filed Aug 21, 2026, 08:30 PM · 2d delay
Shares
19.6k sh
$1.84k per share
Estimated value
-$36.3M
Computed from shares × price
Holdings after
261k sh
Indirect · By Trust

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling 10b5-1 Detected
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, R&D

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.

Original filing · 0001493152-26-039693
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

TAK